VIRTUAL

Date:
12 to 15 August 2021

CME accreditation

23rd Pan American Congress of Rheumatology
August 12-15, 2021
Jointly provided by Postgraduate Institute for Medicine and Pan American League of Associations for Rheumatology

TARGET AUDIENCES

This activity is intended for physicians engaged in the care of patients with rheumatology related conditions.

EDUCATIONAL OBJECTIVES

After completing this activity, the participant should be better able to:

  • Evaluate and treat patients according to the latest advances in the state of the art
  • Identify pathologies according to the different symptoms
  • Apply the new best practices shared by the most advanced professionals and experts in the field
  • Work collaboratively and efficiently with other members of the healthcare team
  • Develop a networking group to exchange experiences and knowledge

TEACHERS

Please view complete faculty 

PROGRAM AGENDA

Check the agenda with the registration and break times by clicking here

JOINT ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Pan American League of Associations for Rheumatology. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN MEDICAL EDUCATION FOR DOCTORS

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 21.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. The existence or absence of COI for everyone in a position to control educational content will be disclosed to participants prior to the start of each activity.

Miguel Albanese
Consulting fees from AbbVie
Fees for Non-CE services from Mead Laboratories

Daniel Aletaha
Consulting fees from AbbVie, Amgen, Lilly, Merck, Novartis, Pfizer, Roche and Sandoz
Research support from AbbVie, Amgen, Lilly, Novartis, Roche, SoBi and Sanofi

Ana Maria Arredondo Gonzalez
Consulting fees from Janssen and Bristol Meyers Squibb
Fees for Non-CE services from Janssen, Bristol Meyers Squibb, Pfizer, Biopas, Amgen Roche and Lilly

Cecelia Asnal
Consulting fees from Pfizer, Lilly and Abbvie

Joshua Baker
Consulting fees from Bristol Myers Squibb, Burns-White, LLC, Pfizer and CorEvitas

Alejandro Balsa
Consulting fees from Pfizer, Roche, Abbvie, BMS, UCB, MSD, Novartis, Nordic, Sandoz, Kern Pharma, Sanofi, Gilead, Galapagos
Fees for Non-CE services from Pfizer, Roche, Abbvie, BMS, UCB, MSD, Novartis, Nordic, Sandoz, Kern Pharma, Sanofi, Gilead, Galapagos

Wilson Bautista-Molano
Consulting fees from Lilly, Novartis and Pfizer

Mihai Bojinca
Consulting fees from Lilly, Novartis and Pfizer
Fees for Non-CE services from AbbVie, Lilly, Novartis, Pfizer, Sandoz, Krka and Zentiva

Antonio Cachafeiro
Consulting fees from AbbVie, Novartis and Sandoz

Juan Canoso
Royalty from UpToDate (2 chapters)

Loreto Carmona
Contracted research with AbbVie, Gebro Pharma, MSD, Novartis, Pfizer, Roche, Sanofi Aventis, Gruenthal and UCB

Gustavo Citera
Consulting fees from Pfizer, Eli Lilly, Janssen, Abbvie, Amgen and Sandoz

Ines Corbacho
Consulting fees from AbbVie and Scienza

Maria de Los Angeles Correa
Consulting fees from AbbVie and Janssen

Carmen de Cunto
Speaker fees from Biogen, Springer Educational Program
Contracted research fees from Clementia/Ipsen

Cristina Drenkard
Consulting fees from SLE Expert Network
Contracted research fees from Let’s Talk About Lupus Education Program

Doruk Erkan
Royalty from UpToDate
Consulting fees from UCB, Alexion
Fees for Non-CE services from GSK, Aurinia
Contracted research fees from ACR/Eular, NIH, GSK, Exagen, LCTC

Polly Ferguson
Consulting fee from Novartis

Ivan Foeldvari
Contracted research fees to be part of the Phase III nintdeanib study for jSSc

Richard Furie
Consulting fees from GlaxoSmithKline, Aurinia Pharmaceuticals

Adrian Gaser
Consulting fees from Boehringer Ingelheim
Fees for Non-CE services from Boehringer Ingelheim, Biotoscana, Raffio and Bagó

Annelise Goecke
Consulting fees from Janssen, AbbVie, BMS and UCB

Jose Gomez Puerta
Consulting fees from Sanofi and Galápagos
Fees for Non-CE services from AbbVie, Astra Zeneca, BMS, Lilly, GSK, MSD, Pfizer, Roche

Ellen Gravallese
Salary from NEJM for Associate Editor position; Salary from ACR for Presidency and President Elect positions
Royalty from textbook “Rheumatology” and UpToDate

Kristen Hayward
Ownership Interest less than 5% in Abbott Labs, AbbVie, Avanos Medical Inc, Teva Pharmaceuticals
Ownership Interest greater than 5% in Merck

Johanna Hernandez
Consulting fees from Pfizer and AbbVie

Sebastian Herrera Uribe
Consulting fees from Janssen-Cilag, Novartis, Amgen, Bristol Myers Squibb and AbbVie
Fees for Non-CE services from Pfizer, Roche, AbbVie, Janssen-Cilag, Novartis, Amgen and Bristol Myers Squibb

Frederic Houssiau
Consulting fees from GSK, Idorsia and Astra Zeneca

Annamaria Iagnocco
Consulting fees from
AbbVie, MSD, Alfasigma, Celltrion, BMS, Celgene, Eli Lilly, Sanofi Genzyme, Galapagos, Gilead, Novartis and Sobi Inc

Carolina Isnardi
Consulting fees from Bristol Myers Squibb
Contracted research fees from Pfizer, Elea Phoenix, AbbVie and Janssen

David Karp
Contracted research fees from Glaxo Smith Kline, Genentech, Bristol Myers Squibb, UCB Pharma, Eli Lilly and Celgene

Kim Lauper
Consulting fees from Pfizer, Celltrion, Viatris and Gilead-Galapagos

Carlos Lozada
Consulting fees from Pfizer, Aurinia, Novartis and Amgen

Claudia Marques
Consulting fees from Novartis and AbbVie

Iain McInnes
Consulting fees from AbbVie, Astra Zeneca, Amgen, BMS, Cabaletta, Causeway Therapeutics, Compugen, Eli Lilly, Gilead, GSK, Janssen, Novartis, Pfizer, Sanofi and UCB
Contracted research fees from BMS, Compugen, GSK, Eli Lilly, Janssen, Novartis, Pfizer and UCB
Ownership interest less than 5% in Causeway Therapeutics, Cabaletta and Compugen

Licia Mota
Consulting fees from Boehringer Ingelheim, AbbVie, Janssen, Pfizer and Amgen
Fees for Non-CE Services from AbbVie, Pfizer, Roche, Janssen, Boehringer Ingelheim and Sandoz

Jose Luis Neyro
Contracted research fees from Stada and Amgen

Eduardo S. Paiva
Consulting fees from Janssen and Amgen
Fee for Non-CE services from Pfizer

Guillermo Pons-Estel
Consulting fees from Pfizer and GSK
Fees for Non-CE services from Janssen, Pfizer and GSK
Contracted research fees from Janssen

Chris Ritchlin
Consulting fees from Amgen, AbbVie, UCB, Lilly, Janssen, Novartis, Bristol Myers Squibb and Sun

Brad Rovin
Consulting fees from Aurinia and GSK

Percival Sampaio
Consulting fees from Boehringer, Lilly, Novartis and Pfizer
Fees for Non-CE services from AbbVie, Boehringer, Lilly, Novartis and UCB

Pedro Santos-Moreno
Consulting fees from Boehringer, Lilly, Pfizer, Janssen, Novartis, Biopas-UCB
Fees for Non-CE services from Lilly, Pfizer, Janssen, Novartis, Amgen and Biopas-UCB
Contracted research fees from Janssen, Pfizer and Bristol Myers Squibb

Fernando Sommerfleck
Consulting fees from AbbVie and Janssen
Fees for Non-CE services from AbbVie, Janssen and Novartis

Enrique Soriano
Consulting fees from AbbVie, Amgen, Janssen, Lilly, Novartis and Pfizer
Fees for Non-CE services from AbbVie, Amgen, Janssen, Lilly, Novartis and Pfizer

Lilith Stange
Consulting fees from Novartis, Sandoz, Roche and AbbVie
Fees for Non-CE services from Fresenius Kabi, AbbVie, Roche, Pfizer, Novatis, Eurofarma and Biopas

Flavio Sztajnbok
Consulting fees from Novartis
Fees for Non-CE services from AbbVie, Alexion and Novartis

Teresa Terreri
Consulting fees from Novartis

Gloria Vasquez
Fees for Non-CE Services from AbbVie, Janssen and Roche

Dan Zhao
Royalty from UpToDate
Consulting fees from Novartis
Contracted research fees from BMS

Dina Arrieta
Consulting fees from AbbVie and Novartis

Cesar Pacheco
Consulting fees from AbbVie, Novartis and Eli Lilly
Contracted research fees for AbbVie, Eli Lilly and Pfizer

Juan Jose Scali
Consulting fees from AbbVie, Pfizer, Bago, Montpellier and TRB Pharma

Alejandro Nitsche
Medical Advisor at Bago Laboratories of Argentina

Luis Fernando Luque
Ownership interest greater than 5% in Adhera Health Inc (Co-founder and Chief Scientific Officer)

John Cush
Consulting fees from AbbVie, Novartis, BMS and Amgen

Carlos Enrique Toro Gutierrez
Consulting fees from Janssen, Roche, Novartis, Boehringer Ingelheim
Fees for Non-CE services from AbbVie and Biopas

All other faculty have nothing to disclose.

ORAL PRESENTATIONS OF ABSTRACTS

 The presenters of the submitted abstracts have nothing to disclose.

PLANNERS AND MANAGERS

The PIM planners and managers have nothing to disclose. The planners and managers of the Pan American League of Rheumatology Associations have nothing to disclose.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.